In our study, in patients with T2DM of both sexes, there was a trend of increase in the circulating levels of adropin in response to the administration of SGLT2 inhibitor dapagliflosin, accompanied by an improvement of cardiac hemodynamics performances. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.